Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GRAPPA Debate: Is Plain Radiography in Psoriatic Disease Still Necessary?

The Journal of rheumatology·2026
Same author

Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies.

RMD open·2026
Same author

Psoriatic Arthritis Features and Risk of Cardiovascular Events: A Nationwide Cohort Study.

Cureus·2025
Same author

Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial.

Nature medicine·2025
Same author

Pregnancy Outcomes After Maternal or Paternal Exposure to Tofacitinib Across Clinical Programs.

The American journal of gastroenterology·2025
Same author

Challenges in Developing Treatment Guidelines in Psoriatic Arthritis.

Rheumatic diseases clinics of North America·2025

Related Experiment Video

Updated: Jul 15, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Economic issues with new rheumatologic therapeutics.

Arthur Kavanaugh1

  • 1Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA 92093-0943, USA. akavanaugh@ucsd.edu

Current Opinion in Rheumatology
|April 7, 2007
PubMed
Summary

Pharmacoeconomic evaluations are vital in rheumatology, especially with new biologic agents. Studies show tumor necrosis factor inhibitors are cost-effective for rheumatic diseases, guiding optimal use of novel therapies.

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Jul 15, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Area of Science:

  • Rheumatology
  • Health Economics
  • Pharmacoeconomics

Background:

  • Pharmacoeconomic evaluations are increasingly critical in medicine, particularly in rheumatology.
  • The advent of highly effective biologic agents for rheumatoid arthritis and other rheumatic diseases necessitates robust economic assessments.
  • Recent studies have updated cost analyses for rheumatic diseases, providing a foundation for evaluating new treatments.

Purpose of the Study:

  • To review the importance and application of pharmacoeconomic evaluations in rheumatology.
  • To highlight the relevance of these studies following the introduction of biologic agents.
  • To discuss the cost-effectiveness of novel therapies, including tumor necrosis factor inhibitors.

Main Methods:

  • Review of recent pharmacoeconomic studies in rheumatology.
  • Analysis of cost-effectiveness data for biologic agents and tumor necrosis factor inhibitors.
  • Discussion of methodologic considerations in long-term pharmacoeconomic evaluations.

Main Results:

  • Pharmacoeconomic studies in rheumatology have been updated and expanded.
  • Tumor necrosis factor inhibitors demonstrate incremental cost-efficacy within acceptable ranges in several clinical scenarios.
  • There is a growing interest in pharmacoeconomic evaluations for rheumatic diseases beyond rheumatoid arthritis.

Conclusions:

  • Pharmacoeconomic evaluations are essential for the optimal utilization of new therapeutic agents in rheumatology.
  • These assessments are crucial for understanding the value of biologic therapies.
  • Continued research and discussion on methodology are needed for long-term evaluations.